Ameriprise
SNDX icon

Ameriprise’s Syndax Pharmaceuticals SNDX Stock Holding History

Ameriprise’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.58M Buy
346,852
+62,607
+22% +$1.3M ﹤0.01% 2252
2026
Q1 		$6.64M Buy
284,245
+1,658
+0.6% +$36K ﹤0.01% 2241
2025
Q4 		$5.94M Buy
282,587
+187,144
+196% +$3.26M ﹤0.01% 2313
2025
Q3 		$1.47M Sell
95,443
-1,231
-1% -$16.1K ﹤0.01% 3167
2025
Q2 		$905K Buy
96,674
+62,446
+182% +$687K ﹤0.01% 3311
2025
Q1 		$420K Buy
34,228
+2,246
+7% +$31.7K ﹤0.01% 3558
2024
Q4 		$423K Sell
31,982
-454,246
-93% -$7.77M ﹤0.01% 3587
2024
Q3 		$9.36M Sell
486,228
-34,852
-7% -$720K ﹤0.01% 1851
2024
Q2 		$10.7M Buy
521,080
+9,579
+2% +$200K ﹤0.01% 1686
2024
Q1 		$12.2M Buy
511,501
+5,492
+1% +$122K ﹤0.01% 1614
2023
Q4 		$10.9M Buy
506,009
+6,488
+1% +$99.7K ﹤0.01% 1697
2023
Q3 		$7.25M Buy
499,521
+143,600
+40% +$2.72M ﹤0.01% 1982
2023
Q2 		$7.45M Buy
+355,921
New +$7.41M ﹤0.01% 2034
2022
Q4 		– Sell
-276,731
Closed -$6.65M – 4041
2022
Q3 		$6.65M Buy
+276,731
New +$6.21M ﹤0.01% 2014
2020
Q3 		– Sell
-10,900
Closed -$162K – 3778
2020
Q2 		$162K Sell
10,900
-20,900
-66% -$318K ﹤0.01% 3528
2020
Q1 		$349K Buy
+31,800
New +$298K ﹤0.01% 3254

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Ameriprise's SNDX Position: Q2 2026 in Review

Ameriprise increased its Syndax Pharmaceuticals (SNDX) stake by 22% in Q2 2026, buying an estimated $1.3M and bringing the position to 346,852 shares worth $7.58M. The position accounts for ﹤0.01% of the portfolio, ranked #2252.

Ameriprise first reported a position in SNDX in Q1 2020 and has held it in 16 quarters since. The position peaked at $12.2M in Q1 2024. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Ameriprise held 346,852 shares of Syndax Pharmaceuticals worth $7.58M as of Q2 2026.
  • Ameriprise bought 62,607 Syndax Pharmaceuticals shares in Q2 2026, an estimated $1.3M.
  • Syndax Pharmaceuticals made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2252 holding.
  • Ameriprise first reported a position in Syndax Pharmaceuticals in Q1 2020 and has held it in 16 quarters since.
  • Ameriprise's Syndax Pharmaceuticals position peaked at $12.2M in Q1 2024.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.